Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 79 |
| Updated: | 4/21/2016 |
| Start Date: | March 2009 |
| End Date: | May 2016 |
Phase I/IIa Study of the Novel Combination of Bendamustine With Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients With Extensive Stage Small Cell Lung Cancer
SCLC constitutes approximately 15% of the 170,000 new cases of lung cancer diagnosed
annually in the United States(1). Extensive-Stage SCLC comprises two thirds of new cases and
is generally considered sensitive to chemotherapy, despite a median time to progression of 4
months(2). SCLC is one of the most aggressive and lethal types of cancer, with a median
survival of 9 months (range 7-11 months) in patients diagnosed with extensive disease(3).
Overall, the majority of patients with SCLC die in less than 2 years (2-year survival rates
generally less than 10%), and the 5-year survival rate is 2.3% for patients with extensive
disease(4). The regimen of etoposide in combination with a platinum (cisplatin or
carboplatin) is generally considered the "standard of care" although a recent Phase III
trial suggests improved survival with the combination of cisplatin/irinotecan(5). Further
evaluation of new agents in combination regimens attempting to overcome the intrinsic drug
resistance seen in extensive-stage SCLC is warranted attempting to improve survival and
achieve palliation of disease-related symptoms.
annually in the United States(1). Extensive-Stage SCLC comprises two thirds of new cases and
is generally considered sensitive to chemotherapy, despite a median time to progression of 4
months(2). SCLC is one of the most aggressive and lethal types of cancer, with a median
survival of 9 months (range 7-11 months) in patients diagnosed with extensive disease(3).
Overall, the majority of patients with SCLC die in less than 2 years (2-year survival rates
generally less than 10%), and the 5-year survival rate is 2.3% for patients with extensive
disease(4). The regimen of etoposide in combination with a platinum (cisplatin or
carboplatin) is generally considered the "standard of care" although a recent Phase III
trial suggests improved survival with the combination of cisplatin/irinotecan(5). Further
evaluation of new agents in combination regimens attempting to overcome the intrinsic drug
resistance seen in extensive-stage SCLC is warranted attempting to improve survival and
achieve palliation of disease-related symptoms.
We are proposing a novel combination of bendamustine plus irinotecan followed by the
standard regimen of etoposide with carboplatin. This will allow the investigation of
response to the novel combination as well as any improvement in outcomes compared to
historical controls.
standard regimen of etoposide with carboplatin. This will allow the investigation of
response to the novel combination as well as any improvement in outcomes compared to
historical controls.
Inclusion Criteria:
- Histologic or cytologic diagnosis of extensive stage SCLC.
- Measurable or assessable tumor parameters.
- ECOG Performance Status 0-2.
- Age between 18 and 79 years (in the State of Alabama > 18).
- Adequate bone marrow, liver and renal function, defined as:
- Absolute neutrophil count (ANC) ≥ 1500/µL
- Hemoglobin ≥ 8g/dl
- Platelet count ≥ 100,000/µL
- SGOT/SGPT ≤ 2 x upper limit of normal or ≤ 5 x upper limit of normal when liver
metastases are present.
- Total bilirubin value ≤ 2 x upper limit of normal.
- Serum creatinine value ≤ 2 x upper limit of normal.
- Fully recovered from any previous surgery (at least 4 weeks since major surgery)
- Must have recovered from prior radiation therapy (at least 3 weeks)
- All subjects must agree to practice approved methods of birth control (if
applicable). A negative pregnancy test must be documented during the screening period
for women of childbearing potential.
- Must provide written informed consent and authorization to use and disclose health
information (HIPAA).
- Extensive-stage SCLC as defined as disease not confined to one hemithorax, including
ipsilateral pleural effusion or pericardial effusion.
- No prior chemotherapy.
Exclusion Criteria:
- Concurrent cancer chemotherapy, biologic therapy or radiotherapy.
- Administration of any investigational drug within 28 days prior to administration of
the current therapy.
- Symptomatic brain metastases; those patients should be treated first with either
whole brain radiation therapy or radiosurgery.
- Concurrent serious infection.
- Concomitant severe or uncontrolled underlying medical disease unrelated to the tumor,
which is likely to compromise patient safety and affect the outcome of the study.
- History of other malignancy (except non-melanoma skin cancer or carcinoma in situ of
the cervix), unless in complete remission and off all therapy for a minimum of 2
years.
- Neuropathy at baseline ≥ Grade 2.
- Any evidence or history of hypersensitivity or other contraindications for the drugs
used in this trial.
- History of chronic diarrhea; or diarrhea (excess of 2-3 stools/day above normal
frequency) in the past 2 weeks.
- History of a positive serology for human immunodeficiency virus (HIV).
- Psychiatric disorder that prevents patients from providing informed consent or
following protocol instructions.
- Pregnant or lactating women.
We found this trial at
2
sites
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
Click here to add this to my saved trials